Mantra Capital Limited Receives BSE In-Principle Approval for Preferential Issue of Equity Shares and Warrants
Mantra Capital Limited received BSE's in-principle approval on March 24, 2026, for preferential issue of 48,25,000 equity shares to non-promoters and 45,00,000 warrants to promoters, both priced at minimum Rs.20/- each. The company must comply with various regulatory requirements and apply for listing within twenty days of allotment, with BSE reserving the right to withdraw approval for non-compliance.

*this image is generated using AI for illustrative purposes only.
Mantra Capital Limited has received in-principle approval from BSE Limited for its preferential issue of equity shares and warrants. The company announced this development on March 25, 2026, following the approval received on March 24, 2026.
Preferential Issue Details
The BSE approval covers the issuance of securities on a preferential basis with specific allocations for different investor categories:
| Security Type: | Quantity | Face Value | Issue Price | Allottee Category |
|---|---|---|---|---|
| Equity Shares: | 48,25,000 | Rs.10/- each | Not less than Rs.20/- | Non-promoters |
| Warrants: | 45,00,000 | Rs.10/- each | Not less than Rs.20/- | Promoters |
The warrants are convertible into an equal number of equity shares of Rs.10/- each. The total value of the preferential issue, at the minimum price of Rs.20/- per security, amounts to Rs.18.65 crore.
Regulatory Compliance Requirements
BSE has outlined several compliance requirements that Mantra Capital must fulfill. The company must ensure strict adherence to provisions of the Companies Act, 2013, Securities Contracts (Regulation) Act, 1956, SEBI Act, 1992, and the Depositories Act, 1996. Additionally, compliance with Chapter V of SEBI ICDR Regulations, 2018, and SEBI LODR Regulations, 2015, is mandatory.
Internal Controls and Trading Restrictions
The exchange has advised the company to strengthen internal controls to monitor trades executed by proposed allottees. Key requirements include:
- Obtaining undertakings from allottees confirming no intra-day trading in company scrip
- Ensuring no sale transactions in company scrip until allotment date
- Verification of compliance with Regulation 167(6) of SEBI ICDR Regulations, 2018
- Monitoring to prevent non-compliances that may impact listing of shares
Post-Allotment Obligations
| Requirement: | Timeline | Details |
|---|---|---|
| Listing Application: | Within 20 days | From date of allotment |
| Applicable Fees: | As per Regulation 14 | LODR Regulations compliance |
| Post-Issue Formalities: | Without delay | Complete documentation required |
As per SEBI circular dated June 21, 2023, any non-compliance with the twenty-day listing application requirement will attract penalties. The company must also note that convertible securities will result in automatic release of excess lock-in period of pre-preferential holdings by depositories.
Important Disclaimers
BSE has clarified that this in-principle approval should not be construed as approval for listing of the securities. The company must separately comply with listing requirements. The exchange reserves the right to withdraw this approval if submitted information is found incomplete, incorrect, misleading, or contravenes applicable regulations.
Mantra Capital Limited, formerly known as Savani Financials Limited, operates under scrip symbol MANTRA with scrip code 511577 on BSE. The approval letter was signed by Marian Dsouza, Assistant Vice President, and Tejas Tandel, Deputy Manager, from BSE Limited.
Historical Stock Returns for Mantra Capital
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.03% | +10.24% | -9.62% | -28.13% | +3.86% | +40.00% |
How will the Rs.18.65 crore capital infusion impact Mantra Capital's expansion plans and competitive positioning in its sector?
What potential dilution effects might existing shareholders face once the 45 lakh warrants are converted to equity shares?
Will Mantra Capital be able to meet the stringent 20-day listing timeline given the complex regulatory compliance requirements?


































